Compare Inovio Pharmaceuticals Inc (INO) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs New York Times Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: New York Times Co is far larger — about 95.7× Inovio Pharmaceuticals Inc's market cap, and New York Times Co pays a 1.38% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and New York Times Co for 81 Days on average.
| INO | NYT | |
|---|---|---|
Market Cap | $112.19M | $10.74B |
Volume | 3,201,278 | 2,096,352 |
Sector | Health | Media |
52-Week High | $2.65 | $85.86 |
52-Week Low | $0.66 | $54.66 |
Typical Hold Time | 43 Days | 81 Days |
Enterprise Value | $83.51M | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
The New York Times Company (NYT) trades at $66.32, up 2.19% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. The stock shows a bullish technical signal with key support at $65-66 and resistance at $67-68, while maintaining robust profitability with 51.41% gross margins and 13.19% net income margin. Recent developments include a declared $0.23 dividend and ongoing AI copyright litigation.
Outlook remains positive with analyst consensus target of $84 representing 27% upside potential, though risks include the shareholder lawsuit alleging bias and competitive pressures in digital media. The company's strong cash flow generation and dividend payments provide shareholder value, while earnings growth trajectory supports continued valuation expansion if execution remains solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
